Moolec Science (MLECW) Income from Continuing Operations (2022 - 2024)
Moolec Science (MLECW) posted Income from Continuing Operations of 3045719.0 for Q4 2024, down 54.49% sequentially from 1971477.0 in Q3 2024, and down 154.0% YoY from 5640313.0 in Q1 2024.
Moolec Science (MLECW) Income from Continuing Operations (2022 - 2024) Analysis & Trends
Moolec Science has reported Income from Continuing Operations for 3 years, with the latest figure at 3045719.0 in Q4 2024.
- Quarterly Income from Continuing Operations fell 154.0% year-over-year to 3045719.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 7996207.0 (down 2980.69% YoY) and the FY2024 annual result came in at 7256093.0, up 86.65% from the prior year.
- Income from Continuing Operations eased to 3045719.0 in Q4 2024 per MLECW's latest filing, from 1971477.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 47960848.0 in Q4 2022 and troughed at 3045719.0 in Q4 2024.
- A 3-year average of 3069591.42 and a median of 1342849.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations surged 69.28% in 2023, then tumbled 220.25% in 2024.
- Over 3 years, Income from Continuing Operations stood at 47960848.0 in 2022, then plunged by 88.24% to 5640313.0 in 2023, then plunged by 154.0% to 3045719.0 in 2024.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 3045719.0, 1971477.0, and 1830682.0 for Q4 2024, Q3 2024, and Q2 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Moolec Science | 8,617.72 | -1.19 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -3.05 Mn |
| Sep 30, 2024 | -1.97 Mn |
| Jun 30, 2024 | -1.83 Mn |
| Mar 31, 2024 | -1.15 Mn |
| Dec 31, 2023 | 5.64 Mn |
| Sep 30, 2023 | -2.02 Mn |
| Jun 30, 2023 | -2.98 Mn |
| Mar 31, 2023 | -358,578.00 |
| Dec 31, 2022 | 47.96 Mn |
| Sep 30, 2022 | -721,426.00 |
| Jun 30, 2022 | -1.52 Mn |
| Mar 31, 2022 | -1.17 Mn |